Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.59 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.59 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24269422 | 1.00 | CRBN (0.59) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24269127 | 0.89 | CRBN (0.60) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25036213 | 0.82 | CRBN (0.66) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20845887 | 0.82 | CRBN (0.70) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31701190 | 0.80 | DDB1 (0.47) | CRBNDDB1IKZF3OPRM1 | |
| SCHEMBL21759498 | 0.80 | CRBN (0.67) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24269178 | 0.79 | DDB1 (0.51) | CRBNDDB1OPRM1 | |
| SCHEMBL29402993 | 0.79 | DDB1 (0.51) | CRBNDDB1OPRM1 | |
| SCHEMBL24132313 | 0.79 | CRBN (0.65) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL31701862 | 0.78 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507333-B | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| EP-4543861-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | Nikang Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| CN-119630644-A | Bifunctional compounds containing pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-119630651-A | Bifunctional compounds containing substituted pyrimidine derivatives for degradation of cyclin-dependent kinase 2 via the ubiquitin proteasome pathway | 霖康疗法公司 | 2025-03-14 | — | — | CN | disclosed |
| WO-2023249970-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023250029-A1 | BIFUNCTIONAL COMPOUNDS CONTAINING SUBSTITUTED PYRIMIDINE DERIVATIVES FOR DEGRADING CYCLIN-DEPENDENT KINASE 2 VIA UBIQUITIN PROTEASOME PATHWAY | NIKANG THERAPEUTICS, INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-116507333-A | Cyclic AMP response element binding protein (CBP) and/or 300KDA adenovirus E1A binding protein (P300) degrading compounds and methods of use | 上海睿跃生物科技有限公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2022042707-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN (SHANGHAI) , INC. (CN) | 2022-03-03 | — | — | WO | disclosed |